| |||||||||||||||||||
![]() ![]() ![]() ![]() ![]() ![]() ![]()
|
![]()
April 3, 2000 Dockets Management Branch (HFA‑305) Re: Draft Guidance for
Industry on Applications Covered by
Section 505(b)(2) Docket No. 99D‑4809 64 Fed. Reg. 68697 (December
8,1999) The Pharmaceutical Research and
Manufacturers of America (PhRMA) submits these comments on the draft
guidance that the Food and Drug Administration (FDA) made available on
December 8, 1999, concerning new drug applications covered by section
505(b)(2) of the Federal Food, Drug, and Cosmetic Act (the Act).[1]
PhRMA is a voluntary, nonprofit association that represents the
country's leading research — based pharmaceutical and biotechnology
companies, which are devoted to research on medicines that allow
patients to lead longer, healthier, and more productive lives. PhRMA's
member companies invest approximately $24 billion annually to discover
and develop new medicines. These companies are the source of nearly all
new drugs that are discovered and marketed throughout the world.
I. Introduction The issuance of this procedural
guidance signals FDA's intention to encourage and facilitate broader use
of 505(b)(2) applications. However, PhRMA is concerned that FDA's
efforts to expand the use of such applications will undermine the public
health and intellectual property protections built into the new drug
application (NDA) and abbreviated new drug application (ANDA) processes.
Accordingly, for the reasons set forth below, PhRMA requests that FDA
withdraw and reissue the draft guidance document to make clear that the
Agency will not approve under section 505(b)(2) of the Act an NDA that
relies on a prior agency finding of safety and efficacy or that in any
fashion relies on an unauthorized reference to proprietary and trade
secret safety and efficacy data contained in an innovator manufacturer's
NDA that is otherwise not available in the public domain. To the extent
that the draft guidance document reflects FDA's interpretation of 21
C.F.R. § 314.54, PhRMA also requests that FDA initiate rulemaking to
modify that regulation in a similar manner. Upon FDA recognition and acceptance
of the above position, PhRMA does believe a 505(b)(2) guidance document
would be useful. Much of the current draft provides a meaningful start.
However, PhRMA has identified additional issues that must be given
consideration and incorporated into any final guidance document.
First, insofar as 505(b)(2) applications may be used for
proposed modifications to approved drugs, the guidance document should
define clearly the types of data needed to demonstrate that a modified
drug is safe and effective. Second, as a practical matter,
there are likely to be few circumstances in which a 505(b)(2) applicant
will rely on data that do not pertain to a listed drug. Thus, to ensure
that drug manufacturers are able to protect their intellectual property
rights, FDA should adopt a presumption that a 505(b)(2) application
relies on data for a listed drug unless the applicant demonstrates
otherwise. II.Section 505(b)(2)
Does Not Authorize FDA to Approve a New Drug Application Based On the
Agency's Prior Finding of Safety and Efficacy In FDA's draft guidance document,
the Agency has stated that it will accept and approve 505(b)(2)
applications for new drug products that rely on "the Agency's finding of
safety and effectiveness for an approved drug, without regard to a right
to rely on such data." See Guidance Document, at 2. PhRMA submits
that section 505(b)(2) does not authorize FDA to follow this course of
action. Section 505(b)(2) was enacted in
1984 as part of the Hatch-Waxman generic drug amendments. The
legislative history of the Hatch-Waxman Amendments indicates that
section 505(b)(2) was intended only to codify FDA's "paper NDA" policy,
which permitted approval of certain drugs based on published studies.[2]
See H.R. 98-857, Part I, 98th Cong., 2d Sess. 32,
reprinted in 1984 U.S.C.C.A.N. 2647, 2665 (noting that section
505(b)(2) addresses filing of "Paper NDAs"). FDA is incorrect in interpreting
section 505(b)(2) as authorizing the agency to approve a new drug by
reference to a prior finding of safety and efficacy based on another
company's proprietary data. The safety and effectiveness data a company
submits when its seeks approval of an NDA are highly confidential, and
thus are protected against unauthorized disclosure and use. See
18 U.S.C. § 1905, 21 U.S.C. § 331(j). The only
circumstances in which FDA can rely on those data to approve another
drug are the circumstances set forth in section 505(j), which provides
for approval of generic drugs. Section 505(j) expressly authorizes FDA
to approve a generic drug based on a prior finding of safety and
efficacy for a pioneer drug, if the generic drug is "the same as" the
pioneer drug in specified ways, and bioequivalent to it. Section
505(b)(2), by contrast, says nothing to authorize approval of a proposed
new drug based on comparison with a previously approved product. Rather,
section 505(b)(2) merely authorizes an NDA applicant to rely on
published literature— was permitted under the paper NDA policy—to
satisfy the "full reports" requirement applicable to all NDAs.
See H.R. 98-857, at 16, reprinted in 1984 U.S.C.C.A.N. at
2649 ("under the Paper NDA procedure, the generic manufacturer may
submit scientific reports, instead of clinical trials, to support
findings of safety and efficacy"). Thus, approval of 505(b)(2)
applications based on prior findings of safety and efficacy is not
authorized by section 505(b)(2) or any other provision of the Act, and
would violate proprietary rights in the data. III. is needed for 505(b)(2)
NDAs The NDA (505(b)(1) and 505(b)(2))
and ANDA procedures are distinguished by the levels of clinical and non
clinical data they require and the exclusivity protections for which
they are eligible. Recent FDA practices have blurred these distinctions,
and this guidance does not clarify them. For example, FDA has approved
versions of certain complex drug products under both 505(b)(2) and ANDA
procedures. In 1998, FDA treated Ferring's Repronex as the "generic"
equivalent of Serono's Pergonal through the ANDA process.[3]
One year later, FDA approved Duramed's Cenestin under a 505(b)(2)
application; however, Cenestin originally had been the subject of an
ANDA referencing Wyeth‑Ayerst's Premarin.[4]
In fact, an FDA representative has
been quoted as stating that FDA's "generic" approval process for
recombinant molecules will rely on the 505(b)(2) NDA "paper" mechanism:
"We are postulating a path for the recombinant molecule that gets an
AB rating in the Orange Book, that does not come in under the [ANDA]
route, it comes in under the (b)(2) route."[5]
This statement, in PhRMA's view, reflects a substantial and
impermissible change in FDA policy. The pharmaceutical industry has long
held the view that A ratings are reserved for generic copies approved
through the ANDA process and simply are not available to modified drugs
approved by 505(b)(2). PhRMA believes that the notion that modified
drugs will be deemed substitutable is not what Congress intended when it
enacted 505(b)(2). Precisely because it is not clear
how 505(b)(2) applications will be used, there is concern within the
industry that the 505(b)(2) process might become a vehicle for the
approval of a vast array of different salts and other chemical variants
of approved small-molecule drugs in addition to its use with respect to
certain large‑molecule and other complex drugs. The experiences
discussed above underscore the need for substantive as well as
procedural guidance from FDA on this subject before FDA embarks further
down this path. 1. FDA must ensure that
505(b)(2) applicants submit sufficient data to support all aspects of
the safety and efficacy of the modified drug product.
As noted above, a section 505(b)(2)
application is an NDA under 505(b) and as such, it must contain full
reports to demonstrate that the new drug in question is safe and
effective. Even when the 505(b)(2) application seeks minor modifications
to an approved drug, significant questions of safety and effectiveness
may arise. Because a 505(b)(2) application serves the same purpose as an
NDA with respect to the modification to the drug or other proposed
change (e.g., a change to the active ingredient), the same
showing of safety and efficacy as is required for a full or supplemental
NDA under section 505(b)(1) is also required to support a 505(b)(2)
modification. FDA has not yet advised the
regulated industry what data will be required to support specific types
of 505(b)(2) changes. FDA should address the substantive aspects of the
505(b)(2) process — specifically, the kinds of studies needed to prove
the safety and effectiveness of a 505(b)(2) modification — in this
guidance document. The review of the clinical and other data supporting
a 505(b)(2) application should be conducted pursuant to a clearly
enunciated policy expressed in a publicly available guidance document.
Rather than establishing uniform
substantive data requirements, the draft guidance indicates that a
505(b)(2) applicant should submit a plan to FDA before submitting the
application. This plan should identify the components of the application
to be supported by publicly available information (not previous FDA
findings which as noted above are not permitted) and should describe any
additional studies to be conducted. The guidance indicates that FDA
"will critique the plan and provide guidance."[6]
This suggests that the clinical studies and other data needed to support
the 505(b)(2) application will be determined in large part by direction
provided by FDA staff to individual applicants. This ad hoc approach
suggests that FDA could apply a variable standard to such applications
that would not necessarily track the rigorous uniform standards applied
to full NDAs. 2. FDA should presume
that a 505(b)(2) applicant is relying on data involving a listed drug unless the
applicant demonstrates otherwise.
From the standpoint of the pioneer
manufacturer, the significant problem with the 505(b)(2) is the
"mismatch" between the publicly available data that the applicant may
rely on and the patent protections that the pioneer manufacturer (which
generated the data) can claim. This is best understood in comparison to
the ANDA process. An ANDA application may rely on data concerning a
listed drug but remains subject to the patent and exclusivity
protections for the same listed drug. A 505(b)(2) application, on the
other hand, because it seeks approval of a drug that is different from a
listed drug, might not provide meaningful patent and data exclusivity
protection(s) to the pioneer. As a practical matter, it is
unlikely a 505(b)(2) application will rely on publicly available
research that was not performed in connection with a listed drug.
Thus, it would be reasonable for the FDA to presume that a 505(b)(2)
applicant is relying on publicly available data involving a listed drug,
notwithstanding that the drug under review is a modified drug or even a
new chemical entity. A 505(b)(2) applicant who fails to identify
one or more listed drugs should be required to demonstrate the reason
why the data it relies on to support a finding of safety and/or efficacy
for the modified drug has not been submitted in connection with a
previously approved NDA or ANDA. IV. Conclusion The Act is clear that FDA must
require the same scope and quality of evidence of safety and efficacy
for a drug approval under 505(b)(2) as that required under 505(b)(1).
Nothing in the Act allows FDA to short circuit that requirement by
relying on data and prior findings of safety and efficacy which it has
no right to divulge or reference. For the foregoing reasons, therefore,
and to avoid engaging further in improper and statutorily unsupported
action that will significantly adversely affect research-based
companies, the FDA should withdraw and/or reissue the
505(b)(2) draft guidance document and should not apply 21 C.F.R.
§ 314.54 to approve NDAs that rely without authorization on non-public
proprietary data. Reissuance of any revised guidance must take into
account additional substantive and procedural safeguards as discussed
above to further ensure proper implementation of section
505(b)(2). Sincerely yours, Matthew B. Van Hook cc:Khyati N. Roberts, CDER
(HFD-6) (5600 Fishers
Lane, rm. 1061, Rockville, MD 20857) [1] Guidance for Industry:
Applications Covered by Section 505(b)(2) (the "Draft Guidance"),
available at
http://www.fda.gov/OHRMS/DOCKETS/98F/994809gd.pdf [2] The policy was
limited to copies of drug products (or closely related forms) marketed
after 1962 and offered for the same indications. [3] Orange Book,
at 3-216 (19th ed. 1999); Generic Recombinant Protein "Paper"
NDA Approval Process Outlined by FDA, THE PINK SHEET, at 32 (April
5, 1999). [4] Id. [5] FDA Generic
Recombinant Protein Approval Process Will Use "Paper" NDAs, HEALTH
NEWS DAILY, at 1 (March 30, 1999)(quoting Roger Williams, then Director,
FDA Office of Pharmaceutical Science)(Emphasis added)> Subsequently,
after leaving FDA, Dr. Williams, speaking as Acting Executive Vice
President and CEO of U.S. Pharmacopoeia, suggested that 505(b)(2)
procedures also could be applied to biological drugs related under the
Public Health Service Act. USP Monograph Could Substitute For ANDA
Chemistry Review, Williams Says, THE PINK SHEET, February 14, 2000,
at 35. [6]
Draft Guidance. at
9 | ||||||||||||||||||
![]() |
Privacy
Policy • Members
Site • Contact
Us • Site
Credits • Site Map • Employment
Pharmaceutical Research and Manufacturers of America |
![]() At the State Level Issues Around the World New Drugs in Development Prescription Drug Costs Seniors and Prescription Drugs Other Issues PhRMA Foundation News |